Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Interview With Charles Gore, Medicines Patent Pool Executive Director

    Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going.

    24 March 2019 | Intellectual Property Watch
  • Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

    RBC Capital Markets analyst Brian Abrahams specifically mentioned a somewhat surprising reason to be excited about Gilead's prospects. He thinks that experimental HIV drug GS-6207 could be a transformative catalyst for Gilead. But GS-6207 is only in phase 1 clinical testing. It could take years for the drug to reach the market.

    24 March 2019 | Motley Fool
  • Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

    Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle.

    14 March 2019 | The New York Times
  • Should the NIH Break HIV Prevention Drug Truvada's Patent?

    Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.

    05 March 2019 | Fortune
  • Hepatitis C Treatment Market to Exceed US$ 71.13 Bn by the end of 2024

    The global hepatitis C treatment market was valued at US$ 23.9 Bn in 2015 and is estimated to be valued at US$ 26.6 Bn by 2016. The market is expected to reach a valuation of US$ 71.13 Bn by the end of 2024, reflecting a cumulative annual growth rate of 13.1% over the forecast period.

    04 March 2019 | Honest Businessman
  • A new way to pay for innovative drugs, provide universal access and not break the bank

    Louisiana, which has a severe hepatitis C problem, is on the cusp of proving to other states that drug companies can make the money they need, while every Medicaid recipient who needs a cure gets one. The state is now on a path to secure immediate treatment for all infected prisoners and people on Medicaid by buying a license from a drug company. It is a concept that can be applied to other ground breaking remedies.

    28 February 2019 | The Conversation
  • US: The struggle to maintain access to lifesaving HIV meds

    President Trump actually proposed a plan in his State of the Union address to end the HIV epidemic in America by 2030. This lofty goal would be thwarted, however, by proposed changes to Medicare Part D that jeopardize the advancements we’ve made in the fight against HIV.

    24 February 2019 | Washington Blade
  • Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP

    Gilead is looking to eventually sub out Truvada for its newer HIV drug Descovy when it comes to pre-exposure prophylaxis. But in the meantime, it’s socking cash into promoting the older brand for PrEP.

    07 February 2019 | FiercePharma
  • CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

    The FDA is allowing CytoDyn to increase the dose of the HIV drug leronlimab which patients in its clinical trial are receiving.

    04 February 2019 | Proactive Investors USA & Canada
  • HIV Drug Prices Keep Rising. Why Is No One Talking About It?

    In order to adequately address the HIV epidemic in the United States, two advocates argue that the high cost of antiretroviral drugs must be addressed.

    30 January 2019 | The Body
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.